scholarly journals Radionuclide Treatment in Pain Palliation

2020 ◽  
Vol 6 (3) ◽  
pp. 423-435
Author(s):  
Umut Elboğa ◽  
Nalan Alan Selçuk
Keyword(s):  
Pain Palliation

Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP

2016 ◽  
Vol 55 (05) ◽  
pp. 188-195 ◽  
Author(s):  
Floor Overbeek ◽  
John de Klerk ◽  
Pieternel Pasker-de Jong ◽  
Alexandra van den Berk ◽  
Rob ter Heine ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Clinical Benefit ◽  
Response Rate ◽  
Clinical Care ◽  
Pain Response ◽  
Pain Palliation ◽  
Breast Cancer Patients ◽  
Routine Clinical Care ◽  
Painful Bone Metastases

Summary Aim: Rhenium-188-HEDP (188Re-HEDP) is an effective radiopharmaceutical for the palliative treatment of osteoblastic bone metastases. However, only limited data on its routine use are available and its effect on quality of life (QoL) has not been studied. Therefore, we evaluated the clinical benefit of 188Re-HEDP in routine clinical care. Patients and methods: Prostate or breast cancer patients with painful bone metastases receiving 188Re-HEDP as a routine clinical procedure were eligible for evaluation. Clinical benefit was assessed in terms of efficacy and toxicity. Pain palliation and QoL were monitored using the visual analogue scale (VAS), corrected for opioid intake, and the EORTC QLQ-C30 Global health status/QoL-scale. Thrombocyte and leukocyte nadirs were used to assess haematological toxicity. Results: 45 and 47 patients were evaluable for pain palliation and QoL, respectively. After a single injection of 188Re-HEDP, the overall pain response rate was 69% and mean VAS-scores decreased relevantly and significantly (p < 0.05). Repeated treatment resulted in similar pain response. The overall QoL response rate was 68% and mean Global health status/QoL-scores increased relevantly and significantly. Haematological side effects were mild and transient. Conclusion: The clinically relevant response on pain and quality of life and the limited adverse events prove clinical benefit of treatment with 188Re-HEDP and support its use in routine clinical care. Its effectiveness appears comparable to that of external beam radiotherapy.

scholarly journals [177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Madhav Prasad Yadav ◽  
Sanjana Ballal ◽  
Marian Meckel ◽  
Frank Roesch ◽  
Chandrasekhar Bal
Keyword(s):  
Overall Survival ◽  
Pain Assessment ◽  
Bone Pain ◽  
Performance Status ◽  
Response Assessment ◽  
Assessment Criteria ◽  
Skeletal Metastases ◽  
Efficacy And Safety ◽  
Pain Palliation ◽  
Global Pain

Abstract Background [177Lu]Lu-DOTA-ZOL has shown promising results from the dosimetry and preclinical aspects, but data on its role in the clinical efficacy are limited. The objective of this study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-ZOL as a bone pain palliation agent in patients experiencing pain due to skeletal metastases from various cancers. Methods In total, 40 patients experiencing bone pain due to skeletal metastases were enrolled in this study. The patients were treated with a mean cumulative dose of 2.1 ± 0.6 GBq (1.3–2.7 GBq) [177Lu]Lu-DOTA-ZOL in a median follow-up duration of 10 months (IQR 8–14 months). The primary outcome endpoint was response assessment according to the visual analogue score (VAS). Secondary endpoints included analgesic score (AS), global pain assessment score, Eastern Cooperative Oncology Group Assessment performance status (ECOG), Karnofsky performance status, overall survival, and safety assessment by the National Cancer Institute’s Common Toxicity Criteria V5.0. Results In total, 40 patients (15 males and 25 females) with a mean age of 46.6 ± 15.08 years (range 24–78 years) were treated with either 1 (N = 15) or 2 (N = 25) cycles of [177Lu]Lu-DOTA-ZOL. According to the VAS response assessment criteria, complete, partial, and minimal responses were observed in 11 (27.5%), 20 (50%), and 5 patients (12.5%), respectively with an overall response rate of 90%. Global pain assessment criteria revealed complete, partial, minimal, and no response in 2 (5%), 25 (62.5%), 9 (22.5%), and 4 (10%) patients, respectively. Twenty-eight patients died and the estimated median overall survival was 13 months (95% CI 10–14 months). A significant improvement was observed in the VAS, AS, and ECOG status when compared to baseline. None of the patients experienced grade III/IV haematological, kidney, or hepatotoxicity due to [177Lu]Lu-DOTA-ZOL therapy. Conclusion [177Lu]Lu-DOTA-ZOL shows promising results and is an effective radiopharmaceutical in the treatment of bone pain due to skeletal metastases from various cancers.

Metastatic bone pain palliation with 89‐Sr and 186‐Re‐HEDP in breast cancer patients

2001 ◽  
Vol 66 (2) ◽  
pp. 101-109 ◽  
Author(s):  
Rosa Sciuto ◽  
Anna Festa ◽  
Rosella Pasqualoni ◽  
Alessandro Semprebene ◽  
Sandra Rea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Bone Pain ◽  
Pain Palliation ◽  
Breast Cancer Patients ◽  
Bone Pain Palliation ◽  
Metastatic Bone Pain

scholarly journals Thermal Ablation of Bone Metastases

2018 ◽  
Vol 35 (04) ◽  
pp. 299-308 ◽  
Author(s):  
A. Kurup ◽  
Matthew Callstrom ◽  
Michael Moynagh
Keyword(s):  
Radiation Therapy ◽  
Bone Metastases ◽  
Thermal Ablation ◽  
Local Tumor Control ◽  
Tumor Control ◽  
Pain Palliation ◽  
Local Tumor ◽  
Image Guided ◽  
Skeletal Related Events ◽  
Percutaneous Thermal Ablation

AbstractImage-guided, minimally invasive, percutaneous thermal ablation of bone metastases has unique advantages compared with surgery or radiation therapy. Thermal ablation of osseous metastases may result in significant pain palliation, prevention of skeletal-related events, and durable local tumor control. This article will describe current thermal ablation techniques utilized to treat bone metastases, summarize contemporary evidence supporting such thermal ablation treatments, and outline an approach to percutaneous ablative treatment.

Stereotactic Body Radiotherapy with Helical Tomotherapy for Pain Palliation in Spine Metastasis

2013 ◽  
Vol 12 (4) ◽  
pp. 363-370 ◽  
Author(s):  
M. S. Kim ◽  
K. C. Keum ◽  
J. H. Cha ◽  
J. H. Kim ◽  
J. S. Seong ◽  
...  
Keyword(s):  
Stereotactic Body Radiotherapy ◽  
Helical Tomotherapy ◽  
Spine Metastasis ◽  
Pain Palliation

Pain Palliation by Percutaneous Acetabular Osteoplasty for Metastatic Hepatocellular Carcinoma

2001 ◽  
Vol 24 (5) ◽  
pp. 346-348 ◽  
Author(s):  
Hirofumi Hokotate ◽  
Yasutaka Baba ◽  
Hisahiko Churei ◽  
Masayuki Nakajo ◽  
Kouichi Ohkubo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pain Palliation ◽  
Metastatic Hepatocellular Carcinoma

Dosimetry of bone seeking beta emitters for bone pain palliation metastases

2021 ◽  
Author(s):  
K Liepe ◽  
I Murray ◽  
G Flux
Keyword(s):  
Bone Pain ◽  
Pain Palliation ◽  
Beta Emitters ◽  
Bone Pain Palliation

scholarly journals Pain Palliation of Bone Metastases Using Magnetic Resonance Guided Focused Ultrasound - Multi-Center Multi-trial Results

2012 ◽  
Vol 23 ◽  
pp. ix463 ◽  
Author(s):  
R. Catane ◽  
D. Gianfelice ◽  
M. Kawasaki ◽  
D. Iozeffi ◽  
S. Kanyev ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Bone Metastases ◽  
Focused Ultrasound ◽  
Pain Palliation

Interventional oncologic procedures for pain palliation

2019 ◽  
Vol 48 (7-8) ◽  
pp. e251-e256
Author(s):  
Dimitrios K. Filippiadis ◽  
Francois H. Cornelis ◽  
Alexios Kelekis
Keyword(s):  
Pain Palliation
Sign in / Sign up

Export Citation Format

Share Document